



NovoLog[®] (insulin aspart) and NovoLog Mix (insulin aspart protamine/insulin aspart) – (authorized brand alternatives)

- On September 6, 2019, [Novo Nordisk announced](#) that they will be launching authorized brand alternative (ABA) versions of their [Novolog \(insulin aspart\)](#) and [Novolog Mix \(insulin aspart protamine/insulin aspart\)](#) injections in vials and pens.
 - The ABA will be made available through Novo Nordisk’s newly established affiliate, Novo Nordisk Pharma Inc., on January 2, 2020.
- Novolog and Novolog Mix are indicated to improve glycemic control in patients with diabetes mellitus.
- According to Novo Nordisk, the ABAs will have a list price 50% lower than the current Novolog/Novolog Mix price as follows:

ABA	List price
Insulin aspart 10 mL vial/1,000 units	\$144.68
Insulin aspart 5x3 mL PenFill [®] (box of 5 pens)/1,500 units	\$268.73
Insulin aspart 5x3 mL FlexPen [®] (box of 5 pens)/1,500 units	\$279.41
Insulin aspart Mix 70/30 10 mL vial/1,000 units	\$150.06
Insulin aspart Mix 70/30 5x3 mL FlexPen (box of 5 pens)/1,500 units	\$279.41

- In addition, Novo Nordisk will be offering the **\$99.00 Cash Card Program for Analog Insulins**.
 - This program allows people with diabetes to purchase up to three vials or two packs of FlexPen/FlexTouch[®] pens of any combination of Novo Nordisk analog insulins (3,000 – 3,600 units total depending on brands) for a flat cost of \$99.00.
 - Studies and clinical experience suggest that these insulin amounts are an adequate supply to cover the monthly needs of most people with diabetes.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.